re: price and indications
1) plasma-derived indications: you can look it up for Europe on the EMEA website with the names of the products given in post #13986 (posted by Dew on price and availability of plasma-derived antithrombin products, 8-March-2005, Biotech Values board)
2) lower price atryn: agree with your thinking re cost pressures(always hoping the very environmentally conscious german consumer doesn't find out about the goats and gets organised...), particularly as IMHO (and based on a very preliminary search only), there is very little good epidemiological and economic data available with respect to the incidence and cost associated with plasma-derived infections for stuff like CJD, meaning, it will be difficult to convince authorities of a higher price in countries where this has to be negotiated based on hard data to underpin a cost-effectiveness analysis. Hence, the decision I assume will be based more on somethign like a budget impact analysis which focuses mainly on how much money it costs e.g. health insurances or a national health system to acquire the drug and what is great is if you can say hello, my product will save you money (we leave out the additional off label use etc. which this board is hoping for for the moment... ;-)
Market Data 
Markets 
AI
